jump to content jump to footer
Radiologist analyzing whole-body MRI scans of multiple myeloma using AI-assisted quantification in mint Lesion

AI-Supported Quantification of Bone Involvement in Multiple Myeloma

Radiologists utilize Whole-Body MRI (WB-MRI) as an established imaging method for multiple myeloma staging [1,3]. Because it avoids ionizing radiation, WB-MRI provides a safe option for serial scans [1]. Furthermore, multi-parametric MRI sequences allow for the visualization of active disease, giving radiologists a clear avenue for quantitative disease burden assessment [1, 4].

However, when integrating comprehensive WB-MRI analysis into standard clinical workflows, radiologists encounter several structural challenges: 

  • Detecting and reporting disease across the entire skeleton is time-intensive [2].
  • Quantifying total disease burden objectively is difficult within standard time constraints [4].
  • Systematically assessing bone marrow heterogeneity presents methodological difficulties [2, 3].
  • Qualitative, text-based reporting can introduce inter-reader variability [1].

AI Capabilities Integrated into mint Lesion

To address these workflow constraints, radiologists can utilize an AI algorithm* integrated into mint Lesion for the detection and segmentation of focal bone lesions. Developed in collaboration with The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, the software serves as a supportive framework that assists the radiologist in three primary areas:

  • Automated Regional Analysis: Radiologists can analyze the disease burden within specific areas, as mint Lesion divides the skeleton into distinct body regions (such as the spine, pelvis, and long bones).
  • Quantitative Disease Measurement: Radiologists obtain the total disease volume across the skeleton. They also gain access to disease volume and Apparent Diffusion Coefficient (ADC) values as a surrogate metric for cellularity, calculated on a per-region basis. To further evaluate the presence of active disease in the bone marrow, radiologists can cross-reference their DWI findings with automatically calculated fat fraction maps.
  • Longitudinal Tracking: Radiologists can track active disease over time by utilizing mint Lesion’s side-by-side comparisons of serial scans, visual charts, and numerical evaluations.

Practical Outcomes for Clinical Workflows

The implementation of these tools aims to shift the reading process from qualitative estimation to data-supported reporting. This approach provides three primary outcomes:

  • Practical Quantification: Supported by automated structural measurements, radiologists can execute full-skeleton quantification efficiently, overcoming the time barriers traditionally associated with manual analysis.
  • Objective Metrics: mint Lesion provides reproducible metrics for risk stratification, moving away from subjective visual estimates like "looks slightly better" to concrete numerical changes.
  • Data for Decision Support: Radiologists can provide oncologists and patients with objective, numerical data to back up their interpretations, offering a clearer baseline for treatment decisions.

Want to read more? Learn how mint Lesion also supports AI-assisted tumor load quantification for bone metastases in prostate cancer.

 

*based on research funded by the National Institute for Health and Care Research (NIHR)

 

Interested in learning how AI-supported structured reporting can support your clinical workflows? Get in touch with our team to learn more about mint Lesion.

References

[1] Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, Østergaard B, Schlemmer HP, Landgren O, Padhani AR. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology. 2019 Apr 1;291(1):5-13. DOI: 10.1148/radiol.2019181949. PMID: 30806604.

[2] Rata M, Blackledge M, Scurr E, Keaveney S, Petts J, Shah C, Jenner M, Drayson M, Owen R, Pratt G, Bird J, Kishore B, Varghese A, Cavenagh J, Macartney C, Kazmi M, Oakervee H, Popat R, Kaiser M, Messiou C. Implementation of whole-body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma. Insights Imaging. 2022 Jul 28;13(1):123. DOI: 10.1186/s13244-022-01253-0. PMID: 35900614.

[3] Messiou C, Porta N, Sharma B, Brown M, Tothill R, Scurr E, Chau K, Tunariu N, Drayson MT, Jenner M, Kaiser MF. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiol Imaging Cancer. 2021 Sep 24;3(5):e210048. DOI: 10.1148/rycan.2021210048. PMID: 34559006.

Mint Medical and Coreline teams coming together to announce partnership
Mint Medical and Coreline Soft integrate AVIEW into mint Lesion to support AI-enabled workflows for structured reporting, Lung-RADS assessment, and longitudinal nodule management in lung cancer screening.
Coreline Soft and Mint Medical Announce Partnership to Advance AI-Enabled Lung Cancer Screening
Coreline Soft and Mint Medical today announced a partnership to advance AI-enabled lung cancer screening, following more than six months of technical…
Read more
Integrated prostate cancer workflow connecting radiology, urology, and pathology through structured reporting, MRI-guided biopsy, longitudinal follow-up, and AI-supported analysis.
mint Lesion supports an end-to-end prostate cancer workflow by connecting radiology, urology, and pathology within a unified digital environment. The platform enables structured mpMRI reporting, MRI/ultrasound fusion biopsy workflows, FHIR-based interoperability, active surveillance, and AI-supported quantification of metastatic disease.
Be Central to the Insight: A Structured, Data-Driven Approach to the End-to-End Prostate Pathway
Digital Integration for Multidisciplinary Teams  In the complex journey of prostate cancer diagnostics, the data contributed by every department is…
Read more
Research poster presentation on standardized tumor response assessments using mint Lesion at the NCCN Annual Conference 2026
Presentation of a research poster by Memorial Sloan Kettering Cancer Center on the use of mint Lesion for structured tumor response assessments and clinical research workflows.
NCCN 2026: Memorial Sloan Kettering Cancer Center Presents Research on Structured Tumor Response Assessments with mint Lesion
Big congratulations to Steven Philemond and Alison Chiaramonte of Memorial Sloan Kettering Cancer Center for presenting their research poster “Use of…
Read more
scroll-top